Agent for treating high-risk impaired glucose tolerance

• US 6,200,958 B1
• Filed: 07/02/1999
• Issued: 03/13/2001
• Est. Priority Date: 12/10/1997
• Status: Expired due to Fees

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Takeda Chemical Industries, Ltd. (Takeda Pharmaceutical Company Limited)
• Inventors: Suzuki, Yoshiharu, Nakaoka, Ichiro, Odaka, Hiroyuki
• Primary Examiner(s): Spivack, Phyllis G.
• Application Number:
  US09/347,028
• Time in Patent Office: 620 Days
• Field of Search: 514/42
• US Class Current: 514/42
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/133 having hydroxy groups, e.g. sphingosine
• CPC Class Codes: A61K 31/7008 Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine

Abstract

The present invention discloses an α-glucosidase inhibitor for prevention of transition from high-risk IGT to diabetes mellitus, for prophylaxis of diabetes mellitus, as well as for treating high-risk IGT.

Claims

1. A method of preventing transition from high-risk impaired glucose tolerance exhibiting a blood glucose level between 170 and 199 mg/dl at 2 hours in a 75 g oral glucose tolerance test to diabetes mellitus exhibiting a blood glucose level of 200 mg/dl or above at 2 hours in a 75 g oral glucose tolerance test in a mammal in need thereof, which comprises administering to said mammal an effective amount of α

-glucosidase inhibitor within 60 minutes before a meal for 13 weeks or longer.

2. The method as claimed in claim 1 wherein the diabetes mellitus is non-insulin-dependent diabetes mellitus.

4. The method as claimed in claim 1 or 3 wherein the α

-glucosidase inhibitor is voglibose.

5. The method as claimed in claim 1 or 3 wherein the α

-glucosidase inhibitor is acarbose.

6. The method as claimed in claim 1 or 3 wherein the α

-glucosidase inhibitor is in a dosage form for oral administration.

7. The method as claimed in claim 1 or 3 wherein the administration dose is in the range of 0.15 to 15 mg per day.

8. The method as claimed in claim 1 or 3 wherein the α

-glucosidase inhibitor is administered for 20 weeks or more.

9. The method as claimed in claim 1 or 3 wherein the α

-glucosidase inhibitor is administered for 28 weeks or more.

3. A method of treating high-risk impaired glucose tolerance exhibiting a blood glucose level between 170 and 199 mg/dl at 2 hours in a 75 g oral glucose tolerance test in a mammal in need thereof, which comprises administering to said mammal an effective amount of α

-glucosidase inhibitor within 60 minutes before a meal for 13 weeks or longer and until the blood glucose level at 2 hours in a 75 g oral glucose tolerance test decreases to the level below 140 mg/dl.